Morgan Stanley’s Regenxbio RGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $23.4M | Sell |
1,953,237
-112,920
| -5% | -$937K | ﹤0.01% | 2951 |
|
|
2026
Q1 | $17.3M | Buy |
2,066,157
+51,369
| +3% | +$540K | ﹤0.01% | 3090 |
|
|
2025
Q4 | $29M | Buy |
2,014,788
+310,520
| +18% | +$3.87M | ﹤0.01% | 2594 |
|
|
2025
Q3 | $16.4M | Buy |
1,704,268
+709,512
| +71% | +$6.27M | ﹤0.01% | 3067 |
|
|
2025
Q2 | $8.17M | Sell |
994,756
-1,072,139
| -52% | -$8.97M | ﹤0.01% | 3623 |
|
|
2025
Q1 | $14.8M | Buy |
2,066,895
+63,584
| +3% | +$473K | ﹤0.01% | 2990 |
|
|
2024
Q4 | $15.5M | Buy |
2,003,311
+653,435
| +48% | +$6.14M | ﹤0.01% | 3007 |
|
|
2024
Q3 | $14.2M | Buy |
1,349,876
+170,024
| +14% | +$2.07M | ﹤0.01% | 3134 |
|
|
2024
Q2 | $13.8M | Sell |
1,179,852
-159,986
| -12% | -$2.49M | ﹤0.01% | 3053 |
|
|
2024
Q1 | $28.2M | Sell |
1,339,838
-480,544
| -26% | -$8.55M | ﹤0.01% | 2311 |
|
|
2023
Q4 | $32.7M | Buy |
1,820,382
+1,438,467
| +377% | +$25.3M | ﹤0.01% | 2162 |
|
|
2023
Q3 | $6.29M | Buy |
381,915
+3,589
| +0.9% | +$65K | ﹤0.01% | 3550 |
|
|
2023
Q2 | $7.56M | Buy |
378,326
+49,761
| +15% | +$959K | ﹤0.01% | 3436 |
|
|
2023
Q1 | $6.21M | Buy |
328,565
+18,596
| +6% | +$411K | ﹤0.01% | 3595 |
|
|
2022
Q4 | $7.03M | Sell |
309,969
-38,104
| -11% | -$861K | ﹤0.01% | 3428 |
|
|
2022
Q3 | $9.2M | Sell |
348,073
-158,675
| -31% | -$4.71M | ﹤0.01% | 3068 |
|
|
2022
Q2 | $12.5M | Buy |
506,748
+102,901
| +25% | +$2.57M | ﹤0.01% | 2833 |
|
|
2022
Q1 | $13.4M | Sell |
403,847
-30,420
| -7% | -$845K | ﹤0.01% | 2555 |
|
|
2021
Q4 | $14.2M | Buy |
434,267
+93,111
| +27% | +$3.17M | ﹤0.01% | 2532 |
|
|
2021
Q3 | $14.3M | Sell |
341,156
-125,672
| -27% | -$4.52M | ﹤0.01% | 2476 |
|
|
2021
Q2 | $18.1M | Buy |
466,828
+204,340
| +78% | +$7.31M | ﹤0.01% | 2263 |
|
|
2021
Q1 | $8.95M | Buy |
262,488
+80,309
| +44% | +$3.43M | ﹤0.01% | 2768 |
|
|
2020
Q4 | $8.26M | Sell |
182,179
-129,673
| -42% | -$4.53M | ﹤0.01% | 2720 |
|
|
2020
Q3 | $8.58M | Buy |
311,852
+122,972
| +65% | +$4.01M | ﹤0.01% | 2160 |
|
|
2020
Q2 | $6.96M | Buy |
188,880
+34,180
| +22% | +$1.27M | ﹤0.01% | 2323 |
|
|
2020
Q1 | $5.01M | Sell |
154,700
-77,198
| -33% | -$3.22M | ﹤0.01% | 2462 |
|
|
2019
Q4 | $9.5M | Buy |
231,898
+33,852
| +17% | +$1.34M | ﹤0.01% | 2488 |
|
|
2019
Q3 | $7.05M | Sell |
198,046
-53,913
| -21% | -$2.18M | ﹤0.01% | 2495 |
|
|
2019
Q2 | $12.9M | Buy |
251,959
+172,653
| +218% | +$8.62M | ﹤0.01% | 1883 |
|
|
2019
Q1 | $4.54M | Sell |
79,306
-225,387
| -74% | -$11.2M | ﹤0.01% | 2804 |
|
|
2018
Q4 | $12.8M | Buy |
304,693
+22,725
| +8% | +$1.33M | ﹤0.01% | 1863 |
|
|
2018
Q3 | $21.3M | Sell |
281,968
-61,375
| -18% | -$4.42M | 0.01% | 1626 |
|
|
2018
Q2 | $24.6M | Buy |
343,343
+54,231
| +19% | +$2.59M | 0.01% | 1453 |
|
|
2018
Q1 | $8.63M | Buy |
289,112
+93,357
| +48% | +$2.72M | ﹤0.01% | 2477 |
|
|
2017
Q4 | $6.51M | Buy |
195,755
+140,248
| +253% | +$4.23M | ﹤0.01% | 2796 |
|
|
2017
Q3 | $1.83M | Sell |
55,507
-12,565
| -18% | -$283K | ﹤0.01% | 3965 |
|
|
2017
Q2 | $1.34M | Buy |
68,072
+25,566
| +60% | +$495K | ﹤0.01% | 4145 |
|
|
2017
Q1 | $821K | Sell |
42,506
-30,414
| -42% | -$587K | ﹤0.01% | 4522 |
|
|
2016
Q4 | $1.35M | Buy |
72,920
+48,814
| +202% | +$933K | ﹤0.01% | 4230 |
|
|
2016
Q3 | $339K | Buy |
24,106
+16,699
| +225% | +$184K | ﹤0.01% | 4749 |
|
|
2016
Q2 | $59K | Sell |
7,407
-851
| -10% | -$9.45K | ﹤0.01% | 5470 |
|
|
2016
Q1 | $89K | Sell |
8,258
-8,928
| -52% | -$114K | ﹤0.01% | 5368 |
|
|
2015
Q4 | $286K | Buy |
17,186
+13,089
| +319% | +$260K | ﹤0.01% | 4895 |
|
|
2015
Q3 | $90K | Buy |
+4,097
| New | +$105K | ﹤0.01% | 5466 |
|
Other funds holding RGNX
RG
Morgan Stanley's RGNX Position: Q2 2026 in Review
Morgan Stanley reduced its Regenxbio (RGNX) stake by 5.5% in Q2 2026, selling an estimated $937K and leaving 1,953,237 shares worth $23.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2951.
Morgan Stanley first reported a position in RGNX in Q3 2015 and has held it in 44 quarters since. The position peaked at $32.7M in Q4 2023. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.
- Morgan Stanley held 1,953,237 shares of Regenxbio worth $23.4M as of Q2 2026.
- Morgan Stanley sold 112,920 Regenxbio shares in Q2 2026, an estimated $937K.
- Regenxbio made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2951 holding.
- Morgan Stanley first reported a position in Regenxbio in Q3 2015 and has held it in 44 quarters since.
- Morgan Stanley's Regenxbio position peaked at $32.7M in Q4 2023.
- 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.